Amwell (NYSE: AMWL) reported Q3 EPS of ($0.48), $0.27 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $61.9 million versus the consensus estimate of $63.17 million.

GUIDANCE:

Amwell sees FY2023 revenue of $257-263 million, versus the consensus of $259.7 million.

For earnings history and earnings-related data on Amwell (AMWL) click here.